Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLA318-2 Nanocrystal Injection in Healthy Participants
NCT07171034Phase 1Recruiting
- Sponsor
- Hunan Kelun Pharmaceutical
- Start
- Sep 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of KLA318-2 in pain and inflammation (4 arms), sponsored by Hunan Kelun Pharmaceutical. Primary endpoint: Incidence and severity of adverse events at 14 days. Started Sep 2025; status: recruiting.
02
Drugs
KLA318-2
03
Conditions
paininflammation
Beyond the preview
Go deeper on NCT07171034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07171034.